Prof. Neeraj Agarwal has reviewed a number of key abstracts from the European Society for Medical Oncology Congress (ESMO 2022).  He shares his thoughts on the conclusions and implications for clinical practice. Watch the video for the key highlights and download the slides for the detailed data.

Dr Ray Manneh Kopp provides his perspectives on data presented at the GU Presidential sessions in a short video review.


Dr Ray Manneh Kopp provides his perspectives on key late-breaking data in prostate cancer and renal cell cancer (RCC) in a short review of the ESMO 2022 GU Presidential sessions:

  • RADICALS-HD trial in prostate cancer patients undergoing post-operative radiotherapy after radical prostatectomy showed encouraging MFS benefits in patients receiving 24 months versus 6 months of ADT
  • COSMIC-313 trial showed that a first-line triplet of cabozantinib plus dual immunotherapy (nivolumab plus ipilimumab) prolonged PFS in RCC patients but also increased toxicity
  • CHECKMATE 914 trial, which investigated nivolumab plus ipilimumab in the adjuvant setting for RCC patients after radical prostatectomy, didn't meet its primary endpoint of DFS

GU CONNECT Update from ESMO 2022

Hi, I'm Dr Ray Manneh and I'm coming to you from ESMO 2022 in Paris, right after the Presidential sessions and I'm going to give you my perspective on the GU abstracts that were presented this year. There were three of them.

The first one is CheckMate 914 that tested nivolumab plus ipilimumab in the adjuvant setting for RCC patients after radical nephrectomy, and the trial didn't meet its primary endpoint of DFS.

The trial highlights the importance of this population and the need that we have to see the results of next trials. It will also increase our expectancy on the overall survival results from KEYNOTE-564.

The second one is the COSMIC-313 trial. It is the first trial to test triplet against doublet therapy. And it's the first trial that included a new standard of care in the comparison arm.

The trial tested cabozantinib plus ipilimumab + nivolumab against nivolumab plus ipilimumab. The study is a positive study. It showed a progression-free survival advantage for the triplet therapy.

The OS results are still immature, but the toxicity profile is increased by the triplet therapy. We need more information to change our minds regarding the choice of first-line treatment, and we will also need the results from other triplet therapy trials.

The third abstract was presented by Dr Parker from the UK and tested the need of adjuvant ADT after radiotherapy done after surgery for prostate cancer.  The study tested two ways of ADT. None ADT versus short-term ADT and short-term ADT versus long-term ADT meaning 24 months of ADT. The primary endpoint was MFS, metastasis-free survival. The study is negative for the comparison between none versus short-term ADT. This population was at really low risk of relapse after this radiotherapy, and it included population with adjuvant and early salvage radiotherapy. The other comparison was between short-term ADT versus long-term ADT, and the results were positive, the intervention of 24 months on ADT increased the likelihood of being metastasis-free after 10 years by six per cent.  

These results show us the need of ADT for the worst population after radical prostatectomy.

In the clinical scenario, we will need to consider these results and compare with the other trials that were presented before.

That's all we have. We will give you more details about ESMO in further videos. Thank you.

Neeraj Agarwal, MD, is a Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine. He is the Senior Director for Clinical Research Innovation at Huntsman Cancer Institute, and the HCI Presidential Endowed Chair of Cancer Research. He also serves as the Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, Salt Lake City, Utah, and directs the Center of Investigational Therapeutics and co-leads the “Experimental Therapeutic Program” at HCI. As a specialist in adult hematology and oncology, Dr Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder and testes). Dr Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences in New Delhi, India, Dr Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa. He then completed a hematology-oncology fellowship at HCI and the University of Utah School of Medicine. Dr Agarwal has received several awards and grants and has authored more than 300 peer-reviewed articles and book chapters. He has given talks at several prestigious regional and national forums and serves as a panel member for the NCCN guideline-committees for bladder and kidney cancer. Dr Agarwal also serves as the overall study chair and/or steering committee member of multiple national and international clinical trials in GU cancers. Dr Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009. He has been appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Committee in 2010. Dr Agarwal is also the recipient of the prestigious 2009-2010 William D. Odell Young Investigator award from the University of Utah’s, Department of Medicine, and the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.

Prof. Neeraj Agarwal has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Arnivas, Astellas, AstraZeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.

Scientific director at Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia. Chief of Genitourinary Unit and Clinical Research Unit. Medical Oncologist at Clínica Portoazul, Barranquilla, Colombia. I completed medical school at Universidad del Norte, Barranquilla Colombia.  Medical oncologist from University Hospital 12 de Octubre in Madrid, Genitourinary Fellow in the GU unit at  University Hospital 12 de Octubre. Master in molecular oncology from Centro de estudios biosanitarios, CNIIO, ESO. Founder of Grupo de Oncología Genitourinaria de Colombia.  Member of SEOM, ACHO and LACOG-GU. I focus my practice on patients with prostate, bladder, kidney and testicular cancer. 

Dr Ray Manneh Kopp has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Dr Reddys, Roche, Janssen, Lilly, MSD, Novartis and Technofarma.

Programme summary
  • clock Duration 4 MIN
  • clock HCPs enrolled 111 HCPs
  • clock Language(s) flag
Play the video now
Other episodes in this series
GU CONNECT Prostate Cancer Update from ESMO 2022

GU CONNECT Prostate Cancer Update from ESMO 2022

Episode 2: Presidential Sessions

Current Episode
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Prostate cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resouces
  • clock 30 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Experts
Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
conference-update Conference update
Oncology 
GI highlights from ESMO 2023

An expert panel discussion hosted by COR2ED and eChinaHealth

  • clock 50 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from BeiGene Europe and SystImmune.
conference-update Conference update
Oncology 
RCC Update from ESMO 2023

How will the latest data impact clinical practice?

Experts
Prof. Laurence Albiges
  • download Downloadable
    Resouces
  • clock 4 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Eisai Europe Limited.
conference-update Conference update
Oncology 
Lung cancer highlights from ESMO 2023

An expert panel discussion hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
conference-update Conference update
Oncology 
Precision Oncology Update From ESMO 2023

How will the latest data impact clinical practice?

Experts
Dr Philipp Ivanyi
  • download Downloadable
    Resouces
  • clock 3 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Bayer.